Lymphoma

The novel drug, IDP-023, is being investigated in patients with relapsed or refractory non-Hodgkin lymphoma or multiple myeloma.

When I told people I have follicular lymphoma, the first reaction I got is "At least you got a good cancer.”

A small study of iopofosine I 131 in patients with pretreated Waldenstrom’s macroglobulinemia showed that the disease control rate was 100%.

After being diagnosed with lymphoma, I decided to supplement my cancer treatment with turkey tail mushrooms.

Researchers have found the CAR-T cell therapy Breyanzi (lisocabtagene maraleucel) to be a cost-effective second-line treatment for patients with relapsed and refractory diffuse large B-cell lymphoma as the drug’s cost rises.

Experts look back on the year in the news regarding bispecific antibodies for the treatment of B-cell lymphomas including CLL and SLL.

The Food and Drug Administration has granted an Orphan Drug Designation to SLS009, a CDK9 inhibitor, for the treatment of patients with relapsed/refractory peripheral T-cell lymphomas.

Patients with relapsed/refractory large B-cell lymphoma treated with CAR-T cell therapy and bendamustine chemotherapy, experienced lower rates of survival and response as well as shorter times until progression, according to recent study findings.

I was asked if I celebrate my cancer journey dates... here is what I said.

Updated safety and subgroup analyses appear consistent with previously reported results from the phase 2 ZUMA-12 study of Yescarta for patients with high-risk large B-cell lymphoma.

Recently approved by the FDA for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), Jaypirca “represents a meaningful advance” in treatment, as one expert explained.

A novel cell therapy demonstrated early efficacy and an acceptable safety profile in patients with graft-versus-host disease undergoing haploidentical stem cell transplantation.

Results from an ongoing phase 2 study show the viability for the use of Brukinsa after patients with previously treated B-cell malignancies are deemed intolerant to the next-generation Bruton tyrosine kinase inhibitor Calquence.

Researchers reported long-lasting responses and no new safety concerns in patients with relapsed/refractory follicular lymphoma during the 2023 ASH Annual Meeting and Exposition.

The three-year final analysis of efficacy and safety of the REACH3 trial showed that patients with steroid-refractory or dependent chronic graft-versus-host disease benefited more with Jakafi compared with the best available treatment.

Autologous hematopoietic cell transplantation, compared with CAR-T cell therapy, resulted in lower rates of relapse and improved progression-free survival in patients with relapsed large B-cell lymphoma while they were in complete response.

Data from the ZUMA-7 trial shows that age alone should not be a barrier of consideration of administering CAR-T cell therapy to patients with large B-cell lymphoma, says Dr. Marie José Kersten.

Tecartus is safe and effective in real-world patients with relapsed/refractory mantle cell lymphoma, regardless of the presence of high-risk features.

After all these blogs, there’s still one side effect I haven’t talked about.

From FDA concerns to a potential new drug, CAR-T cell therapies were dominating oncology headlines last week.

The Food and Drug Administration granted a Breakthrough Therapy Designation to Epkinly to treat patients with relapsed or refractory follicular lymphoma.

If you have scanxiety, you aren't alone.

An expert discusses the FDA’s investigation into the possible association between CAR-T cell therapy and secondary T-cell malignancies.

As we all know, added stress for patients with cancer is never a good thing.

The FDA announced rare instances of secondary diseases or cancers from CAR-T cell therapy, though this is not the first time that oncology treatments have been associated with secondary diseases.